Formulation and in vitro/in vivo evaluation of levodopa transdermal delivery systems

International Journal of Pharmaceutics

Volumn 456, Issue 2, 2013, Pages 432-436

  Lee, Kyung Eun ^a   Choi, Yun Jung ^a   Oh, Byu Ree ^a   Chun, In Koo ^b   Gwak, Hye Sun ^a  

^a Ewha Womans University   (South Korea)

^b Dongduk Women's University   (South Korea)

Author keywords

Levodopa; Permeation; Pharmacokinetics; Transdermal delivery system

Indexed keywords

2 PROPANOL; ALCOHOL; FATTY ACID; LEVODOPA; LINOLEIC ACID; MACROGOL 400; MYRISTIC ACID ISOPROPYL ESTER; OLEYL ALCOHOL; PENETRATION ENHANCING AGENT; PROPYLENE GLYCOL;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG PENETRATION; EVALUATION; FEASIBILITY STUDY; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TIME TO MAXIMUM PLASMA CONCENTRATION; TRANSDERMAL DRUG ADMINISTRATION;

AAAD; C-DOPA; CARBIDOPA; DISODIUM ETHYLENEDIAMINE TETRAACETIC ACID; EA; EDTANA(2); ETHYL ALCOHOL; HAS; HEPTANESULPHONATE; IPA; IPM; ISOPROPYL ALCOHOL; ISOPROPYL MYRISTATE; L-AROMATIC AMINO ACID DECARBOXYLASE; L-DOPA; LBF1944; LBF2609; LEVODOPA; OA; OLEOYL MACROGOL-6 GLYCERIDE; OLEYL ALCOHOL; PARKINSON'S DISEASE; PD; PEG400; PERMEATION; PG; PGL; PGMC; PGML; PHARMACOKINETICS; POLYETHYLENE GLYCOL 400; PRESSURE SENSITIVE ADHESIVE; PROPYLENE GLYCOL; PROPYLENE GLYCOL LAURATE; PROPYLENE GLYCOL MONOCAPRYLATE; PROPYLENE GLYCOL MONOLAURATE; PROPYLENE GLYCOL-8 GLYCERYL LINOLEATE; PSA; TDS; TRANSDERMAL DELIVERY SYSTEM; TRANSDERMAL DELIVERY SYSTEMS;

ADMINISTRATION, CUTANEOUS; ANIMALS; CHEMISTRY, PHARMACEUTICAL; DRUG DELIVERY SYSTEMS; DRUG EVALUATION, PRECLINICAL; HUMANS; LEVODOPA; MALE; MICE; MICE, HAIRLESS; ORGAN CULTURE TECHNIQUES; RATS; RATS, SPRAGUE-DAWLEY; SKIN ABSORPTION;

EID: 84886724155     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2013.08.044     Document Type: Article

References (19)

1. H.C. Ansel, N.G. Popovich, and L.V. Allen Pharmaceutical Dosage Forms and Drug Delivery Systems 1995 Williams and Wilkins Malvern 357 372
2. B.J. Aungst, N.J. Rgers, and E. Shefter Enhancement of naloxone penetration through human skin in vitro using fatty acids, fatty alcohols, surfactants, sulfoxides and amides Int. J. Pharm. 33 1986 225 234 (Pubitemid 17197807)
3. B.W. Barry Mode of action of penetration enhancers in human skin J. Control. Release 6 1987 85 97 (Pubitemid 18017724)
4. Y.A. Cho, and H.S. Gwak Transdermal delivery of ketorolac tromethamine: effects of vehicles and penetration enhancers Drug Dev. Ind. Pharm. 30 2004 557 564 (Pubitemid 38924625)
5. J.J. Chen Parkinson's disease J.T. Dipiro, R.L. Talbert, G.C. Yee, G.R. Matzke, B.G. Wells, M.L. Posey, Pharmacotherapy: A Pathophysiologic Approach 2008 McGraw Hill New York 977 988
6. M. Contin, R. Riva, F. Albani, and A. Baruzzi Pharmacokinetic optimization in the treatment of Parkinson's disease Clin. Pharmacokinet. 6 1996 463 481 (Pubitemid 26175755)
7. E.R. Cooper Increased skin permeability for lipophilic molecules J. Pharm. Sci. 73 1984 153 156
8. E.R. Cooper, E.W. Merritt, and R.L. Smith Effect of fatty acids and alcohols on the penetration of acyclovir across human skin in vitro J. Pharm. Sci. 74 1985 688 689 (Pubitemid 15042137)
9. C.G. Cotzias, M.H. Van Woert, and L.M. Schiffer Aromatic amino acids and modification of parkinsonism New Engl. J. Med. 276 1967 374 379
10. H.S. Gwak, and I.K. Chun Effect of vehicles and penetration enhancers on the in vitro percutaneous absorption of tenoxicam through hairless mouse skin Int. J. Pharm. 236 2002 57 64 (Pubitemid 34219373)
11. P.G. Green, R.H. Guy, and J. Hadgraft In vitro and in vivo enhancement of skin permeation with oleic acid and lauric acids Int. J. Pharm. 48 1988 103 111
12. A. Hoelgaard, B. Møllgaard, and E. Baker Vehicle effect on topical drug delivery: IV. Effect of N-methylpyrrolidone and polar lipids on percutaneous drug transport Int. J. Pharm. 43 1988 233 240
13. B.T. Johnston, Q. Li, J.A. Castell, and D.O. Catell Swallowing and esophageal function in Parkinson's disease Am. J. Gastroenterol. 90 1995 1741 1746
14. S.A. Jung, H.S. Gwak, I.K. Chun, and S.Y. Oh Levodopa transport through skin using iontophoresis: the role of electroosmosis and electrorepulsion J. Korean Pharm. Sci. 38 2008 31 38
15. T. Müller, C. Erdmann, D. Bremen, W.E. Schmidt, S. Muhlack, D. Woitalla, and O. Goetze Impact of gastric emptying on levodopa pharmacokinetics in Parkinson disease patients Clin. Neuropharmacol. 29 2006 61 67 (Pubitemid 44357153)
16. D. Nyholm Pharmacokinetic optimization in the treatment of Parkinson's disease: an update Clin. Pharmacokinet. 45 2006 109 136 (Pubitemid 43290827)
17. C.S. Okereke Role of integrative pharmacokinetic and pharmacodynamic optimization strategy in the management of Parkinson's disease patients experiencing motor fluctuations with levodopa J. Pharm. Pharm. Sci. 5 2002 146 161
18. N. Simon, R. Gantcheva, B. Bruguerolle, and F. Viallet The effects of a normal protein diet on Levodopa plasma kinetics in advanced Parkinson's disease Parkinsonism Relat. Disord. 10 2004 137 142 (Pubitemid 38251657)
19. M. Yamada, Y. Uda, and Y. Tanigawara Mechanism of enhancement of percutaneous absorption of molsidomine by oleic acid Chem. Pharm. Bull. 35 1987 3399 3406 (Pubitemid 17133558)